Literature DB >> 9827693

Binding of CDK9 to TRAF2.

T K MacLachlan1, N Sang, A De Luca, P L Puri, M Levrero, A Giordano.   

Abstract

CDK9 has been recently shown to have increased kinase activity in differentiated cells in culture and a differentiated tissue-specific expression in the developing mouse. In order to identify factors that contribute to CDK9's differentiation-specific function, we screened a mouse embryonic library in the yeast two-hybrid system and found a tumor necrosis factor signal transducer, TRAF2, to be an interacting protein. CDK9 interacts with a conserved domain in the TRAF-C region of TRAF2, a motif that is known to bind other kinases involved in TRAF-mediated signaling. Endogenous interaction between the two proteins appears to be specific to differentiated tissue. TRAF2-mediated signaling may incorporate additional kinases to signal cell survival in myotubes, a cell type that is severely affected in TRAF2 knockout mice.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9827693

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

1.  Selective inhibition of CDK7 ameliorates experimental arthritis in mice.

Authors:  Yong Xia; Li-Ying Lin; Mei-Ling Liu; Zheng Wang; Hong-Hai Hong; Xu-Guang Guo; Guo-Quan Gao
Journal:  Clin Exp Med       Date:  2014-08-23       Impact factor: 3.984

2.  Increased cyclin T1 expression as a favorable prognostic factor in treating gastric adenocarcinoma.

Authors:  Jong-Shiaw Jin; Lien-Fu Lin; Jui-Chang Chen; Chia-Chi Huang; Jeng-Horng Sheu; Wenlung Chen; Tang-Yi Tsao; Chih-Wei Hsu
Journal:  Oncol Lett       Date:  2015-09-25       Impact factor: 2.967

3.  Molecular karyotypes of Hodgkin and Reed-Sternberg cells at disease onset reveal distinct copy number alterations in chemosensitive versus refractory Hodgkin lymphoma.

Authors:  Marilyn L Slovak; Victoria Bedell; Ya-Hsuan Hsu; Dolores B Estrine; Norma J Nowak; Maria L Delioukina; Lawrence M Weiss; David D Smith; Stephen J Forman
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

Review 4.  A curious case of cyclin-dependent kinases in neutrophils.

Authors:  Ramizah Syahirah; Alan Y Hsu; Qing Deng
Journal:  J Leukoc Biol       Date:  2022-02-21       Impact factor: 6.011

Review 5.  Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents.

Authors:  A E Leitch; C Haslett; A G Rossi
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

6.  Positive cyclin T expression as a favorable prognostic factor in treating gastric gastrointestinal stromal tumors.

Authors:  Lien-Fu Lin; Jong-Shiaw Jin; Jui-Chang Chen; Chia-Chi Huang; Jeng-Horng Sheu; Wenlung Chen; Tang-Yi Tsao; Chih-Wei Hsu
Journal:  Mol Clin Oncol       Date:  2016-03-30

7.  Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development.

Authors:  Gaetano Romano
Journal:  ISRN Oncol       Date:  2013-06-06

Review 8.  Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.

Authors:  Vladimír Krystof; Sonja Baumli; Robert Fürst
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.